Oluyemi Okupe Sells 101,993 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 101,993 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66. Following the completion of the sale, the chief financial officer now directly owns 109,392 shares in the company, valued at approximately $3,240,191.04. This represents a 48.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total transaction of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.79, for a total transaction of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.60, for a total value of $169,491.40.

Hims & Hers Health Trading Down 2.2 %

Shares of HIMS stock traded down $0.69 on Tuesday, reaching $30.67. The company had a trading volume of 19,581,394 shares, compared to its average volume of 9,741,340. The stock has a market cap of $6.70 billion, a PE ratio of 69.73 and a beta of 1.06. The company has a 50-day moving average of $20.85 and a 200-day moving average of $19.44. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $31.68.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.04) EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on HIMS shares. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen reiterated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.71.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after buying an additional 136,907 shares during the period. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares in the last quarter. State Street Corp raised its holdings in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the period. Geode Capital Management LLC lifted its position in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.